title: Glucose insulin potassium infusion improves systolic function in patients with chronic ischemic cardiomyopathy.
abstract: OBJECTIVE
  We assessed the effects of glucose-insulin-potassium (GIK) by echocardiography in stable patients with ischemic dysfunction.
  
  
  METHODS
  Twelve male patients with stable coronary disease (SCD) and ejection fraction (EF) <45% were studied for systolic function. GIK (glucose 30%, 300 insulin units and KCl 6 g/l) was infused at 1 ml/kg per h over 20 min. Hemodynamic and echocardiographic measurements were recorded at rest (T(0)), at the end (20 min) of GIK infusion (T+20), 20 and 40 min after the end of the infusion (T+40 and T+60).
  
  
  RESULTS
  At T+20, a significant decrease in WMSI (wall motion score index) was observed compared with T(0) (2.16+/-0.14 vs. 2.30+/-0.16: P<0.05). An increase in EF was reported at T+40 and T+60 compared with T(0) (44.1+/-7.8% and 53.3+/-11.6% vs. 35.6+/-4.5%, respectively: P<0.01). A decrease in WMSI was observed at T+40 and T+60 compared with rest (2.02+/-0.17 and 1.93+/-0.11 vs. 2.30+/-0.16, respectively: P<0.01).
  
  
  CONCLUSIONS
  Our present work suggests that GIK infusion improves systolic function in patients with SCD and ejection fraction <45%. Further studies are needed to determine if short-term GIK infusion could be useful for therapeutic or diagnostic strategies in these patients.
authors.affiliation: Cardiology Department, University Hospital, Dijon, France. yves.cottin@chu-dijon.fr
authors.forename: Yves
authors.initials: Y
authors.lastname: Cottin
authors.forename: Isabelle
authors.initials: I
authors.lastname: Lhuillier
authors.forename: Laurent
authors.initials: L
authors.lastname: Gilson
authors.forename: Marianne
authors.initials: M
authors.lastname: Zeller
authors.forename: Caroline
authors.initials: C
authors.lastname: Bonnet
authors.forename: Christine
authors.initials: C
authors.lastname: Toulouse
authors.forename: Pierre
authors.initials: P
authors.lastname: Louis
authors.forename: Luc
authors.initials: L
authors.lastname: Rochette
authors.forename: Claude
authors.initials: C
authors.lastname: Girard
authors.forename: Jean-Eric
authors.initials: JE
authors.lastname: Wolf
mesh_terms: D000328:Adult; D000368:Aged; D001794:Blood Pressure / Q000187:drug effects*; D009202:Cardiomyopathies / Q000150:complications / Q000188:drug therapy*; D002908:Chronic Disease; D004452:Echocardiography; D005500:Follow-Up Studies; D005947:Glucose / Q000008:administration & dosage*; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D007260:Infusion Pumps; D007328:Insulin / Q000008:administration & dosage*; D008297:Male; D008875:Middle Aged; D011188:Potassium / Q000008:administration & dosage*; D013318:Stroke Volume / Q000187:drug effects; D016896:Treatment Outcome; D018487:Ventricular Dysfunction, Left / Q000150:complications / Q000188:drug therapy
chemical_list: D007328:Insulin; C030396:glucose-insulin-potassium cardioplegic solution; D005947:Glucose; D011188:Potassium